ArticleDigestive diseases and sciences2026
BECN1 Protects Against Intestinal Ischemia/Reperfusion Injury by Promoting NLRP3 Ubiquitination and Suppressing Inflammasome Activation.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Myeloid-specific Becn1 deficiency elicits spontaneous pulmonary injury and exacerbates acute lung injury.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveIntestinal ischemia/reperfusion (I/R) injury causes severe inflammation and disruption of the epithelial barrier, often leading to life-threatening complications. Although autophagy is known to provide tissue protection during I/R, the mechanisms linking autophagy to inflammasome regulation remain unclear. This study aimed to investigate the role of Beclin 1 (BECN1) in regulating NLRP3 inflammasome activation during intestinal I/R injury.
methodsIntestinal I/R models were used to examine changes in BECN1 expression in intestinal epithelial cells. Conditional knockout mice lacking Becn1 in intestinal epithelial cells were generated to evaluate its functional role in vivo. Autophagic flux, NLRP3 ubiquitination, inflammasome activation, and inflammatory cytokine production were assessed using molecular and biochemical approaches. In addition, the therapeutic potential of a cell-penetratingTAT-BECN1 peptide was evaluated in the I/R model.
resultsBECN1 expression was significantly upregulated in intestinal epithelial cells following I/R injury. Mechanistically, BECN1 promoted ubiquitin-dependent degradation of NLRP3, thereby limiting inflammasome activation. Conditional deletion of Becn1 in intestinal epithelial cells exacerbated intestinal injury and increased inflammatory cytokine production. Conversely, administration of the TAT-BECN1 peptide restored autophagic flux, enhanced NLRP3 ubiquitination, and attenuated epithelial damage and inflammation after I/R.
conclusionBECN1 protects against intestinal I/R injury by promoting NLRP3 ubiquitination and suppressing inflammasome activation through the autophagy pathway. These findings reveal a previously unrecognized mechanism linking autophagy to inflammasome regulation and suggest that targeting the BECN1-autophagy axis may represent a promising therapeutic strategy for intestinal I/R injury.
Indexed as
Identifiers
41831153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.